Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN), Clairity, and MagView announced a collaboration on Nov 25, 2025 to deliver the first integrated platform combining genotype and AI-derived phenotype for breast cancer risk assessment.
The integration links Myriad’s MyRisk with RiskScore hereditary cancer test, Clairity Breast (the FDA-authorized AI mammogram risk estimator), and MagView’s Luminary Risk workflow to provide clinicians a unified, actionable view of five-year breast cancer risk from routine mammograms and genetics.
The partners say the platform aims to identify more women at elevated risk and support earlier, personalized interventions while preserving clinical workflow efficiency.
Positive
- FDA-authorized AI mammogram risk estimator (Clairity Breast)
- Genotype+phenotype integration via MyRisk with RiskScore and Clairity in MagView
- Platform workflow integration across US breast imaging centers
Negative
- No commercial terms, pricing, adoption timelines, or revenue impact disclosed
Insights
Integrated genotype+phenotype risk view may materially improve individual breast‑cancer risk identification and clinical actionability.
The collaboration links Clairity Breast AI risk scores with Myriad genetic RiskScore results inside MagView workflow tools, creating a single, combined clinical risk record that clinicians can review during routine mammography visits. This aligns two complementary data types—image‑derived phenotype and hereditary/genetic genotype—so clinicians see both risk signals together rather than separately.
Dependencies and risks include clinician adoption, EHR/workflow integration quality, and how programs translate combined scores into follow‑up care decisions; none of these operational details are specified. Watch implementation scale and documented clinical pathways, especially over the next 12–18 months and any published performance data tied to the integrated output on or after
Embedding combined risk outputs into MagView’s platform should reduce friction and improve actionable delivery of risk information.
MagView’s Luminary Risk platform will host both Clairity’s AI risk and Myriad’s MyRisk with RiskScore test results, which should streamline capture, visualization, and reporting of risk without separate manual steps. That centralization can cut administrative tasks and speed clinician access to consolidated risk data at point of care.
Key operational checks are data mapping, interoperability testing, and consent/data governance details not disclosed here. Monitor rollout milestones, integration validation in clinical settings, and any workflow metrics or adoption rates reported in the next
Actionable offering helps enable earlier, more personalized breast cancer interventions
BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens.
The agreement brings together three leaders in breast cancer:
- Clairity – developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram
- Myriad Genetics – a leader in molecular diagnostic testing and precision medicine, offering the MyRisk® Hereditary Cancer Test with RiskScore®, which combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk
- MagView – a leader in comprehensive software solutions for breast imaging centers
For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk platform, which supports breast cancer risk assessment programs across the United States.
“By integrating directly with MagView alongside Myriad, we are giving clinicians a more complete and actionable view of risk than can be achieved using age and family history alone,” said Jeff Luber, CEO, Clairity, “Using AI-powered risk assessment, Clairity Breast identifies women at the highest risk from a routine mammogram.”
“Effective screening of individuals with elevated risk of cancer is an important part of the cancer care continuum,” said Sam Raha, President and CEO, Myriad Genetics. “By pairing the MyRisk Hereditary Cancer Test with Clairity’s AI-powered risk assessment within MagView’s workflow, we aim to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer.”
“Our platform streamlines how risk information is captured, interpreted, and acted on,” said Bryan Chapin, President and CEO, MagView. “Integrating Clairity and MyRisk into one platform gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency.”
About Clairity
Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act earlier, save lives, and lower the overall cost of cancer care. To learn more about indications for use, visit: https://clairity.com/clairity-breast/.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
About MagView
MagView is the leader in breast imaging workflow solutions for mammography reporting, tracking, workflow, compliance, and high-risk screening. Headquartered in Fulton, Maryland, MagView’s Luminary Risk software embeds into EHRs to enable breast centers to adopt a more personalized approach to breast cancer screening, focusing on patient experience and staff efficiency. MagView is utilized by more than 2,500 facilities across the U.S., including many of the nation’s top cancer centers. For more information about MagView, please visit www.magview.com.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to how the joint collaboration aims to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens; expectations that integrating Clarity into MagView alongside Myriad gives clinicians a more complete and actionable view of risk than can be achieved using age and family history alone; by pairing the MyRisk Hereditary Cancer Test with Clairity’s AI-powered risk assessment within MagView’s workflow, Myriad aims to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer; and statements regarding the potential for the integration of Clairity Breast and MyRisk into one platform to give providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
What did Myriad Genetics (MYGN) announce on November 25, 2025 about breast cancer risk?
How does the Clairity–Myriad–MagView platform affect MYGN patients and clinicians?
Is Clairity Breast FDA authorized as part of the MYGN collaboration announced Nov 25, 2025?
Will the Myriad (MYGN) collaboration change clinical workflow at imaging centers?
Does the Nov 25, 2025 announcement disclose pricing or revenue guidance for Myriad (MYGN)?
